Background. Factors determining the individual susceptibility to head and neck squamous cell carcinoma (HNSCC) are still largely unknown. An imbalance between enzymes involved in the toxification and detoxification of (pre)-carcinogens closely related to HNSCC, which may appear during smoking and alcohol consumption, may play a role. Genetic polymorphisms in glutathione S-transferases (GSTs) often result in altered detoxification, which may contribute to individual susceptibility to HNSCC.
As a result of conjugation with glutathione, the potential carcinogens are eliminated, and DNA or other important biomolecules are protected against damage or adduct formation. [2] [3] [4] [5] In humans, the GST enzymes can be divided into five main classes: Alpha (GSTA), Mu (GSTM), Pi (GSTP), Theta (GSTT), and Zeta (GSTZ). Each class consists of one or more isoenzymes with different, but sometimes overlapping, substrate specificity. 4, 5 At present, genetic polymorphisms have been demonstrated for GSTM1, GSTT1, and GSTP1. [5] [6] [7] [8] [9] Polymorphisms in the GSTP1 gene consist of the variant genotypes GSTP1 AB and GSTP1 BB next to the wild-type GSTP1 AA. The frequency of GSTP1 AA in healthy controls ranges from 42%-69%. [9] [10] [11] [12] [13] [14] A transition of adenine (A) to guanine (G) at nucleotide 313 in exon 5 of the GSTP1 gene results in substitution of isoleucine (Ile) to valine (Val) at position 104 in the amino acid sequence of the protein. 7, 15, 16 The valine variants exhibit lower specific activity and affinity for the electrophilic substrates of the enzyme. 7, 13, 15 The valinecontaining homozygous variant, GSTP1 BB, occurs in approximately 10% of healthy controls, whereas the heterozygous Ile-Val variant, GSTP1 AB, occurs in approximately 35% of controls. [9] [10] [11] [12] [13] [14] The GSTP1 gene encodes for the isoenzyme GSTP1-1. The GSTP1-1 enzyme level has been extensively studied in relation to tobaccoassociated malignancies. The GSTP1-1 enzyme is overexpressed in many preneoplastic and neoplastic lesions. Elevated tissue levels of GSTP1-1 enzyme have been found in stomach, colorectal, bladder, oral, pharynx, larynx, lung, skin, and breast tumors compared with normal tissues of matched controls. 5, [17] [18] [19] [20] [21] [22] The GSTP1-1 enzyme may be involved in the resistance to chemotherapeutic agents and radiotherapy. 5, [23] [24] [25] Because GSTP1-1 is also involved in the metabolism and subsequent removal of anticancer drugs, high levels of GSTP1-1 in tumors may contribute to drug resistance in several different cancers. [26] [27] [28] However, there are also contradictory reports.
Because the amino acid changes are the result of the polymorphisms close to the area of hydrophobic binding site for electrophiles, the homozygous GSTP1 BB and heterozygous GSTP1 AB gene products result in a decreased specific activity and affinity for electrophilic compounds. 7 Thus, the altered metabolic activity of these enzymes could influence susceptibility to head and neck cancer. Earlier we investigated the possible involvement in HNSCC and in benign head and neck lesions of genetic polymorphisms in CYP1A1, GSTM1, and GSTT1, but we found no enhanced rates of GST null genotypes in the cancer population. 29 Earlier work from our group showed that the GSTP1-1 enzyme, in a quantitative sense, is by far the most important detoxification enzyme in human head and neck tissues. 30 Therefore, we investigated genetic polymorphisms in GSTP1 in a large series of patients with HNSCC and in matched healthy controls. We also evaluated exposure to alcohol and tobacco of these subjects and evaluated the potential effect modification between GSTP1 polymorphisms and these environmental exposures. Exposure Assessment, Blood Sampling, and Assessment of Genetic Polymorphisms. Information on tobacco use and alcohol consumption was collected for all patients and controls by interview. The amount of pack years (PY) was calculated as the number of years smoking × the number of packs a day (assuming 20 cigarettes ‫ס‬ 1 pack). Never smokers were defined as subjects who had smoked less than 1 pack year cumulatively.
MATERIALS AND METHODS

Patients and
Blood was collected by venapuncture in sterile siliconized EDTA K3 (15%) 4-mL Vacutainer tubes (Becton Dickinson, San Jose, CA). Immediately after collection, whole blood was stored at −20°C until use. Genomic DNA was isolated from whole blood using the Wizard genomic DNA purification kit, according to the instructions of the manufacturer (Promega, Madison, WI).
Genetic polymorphisms were detected by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). For studying the genetic polymorphism in GSTP1, a primer set (105F and 105R) was designed so that the presence of the A to G substitution at codon 313 resulted in the appearance of an Alw261 restriction enzyme site. 9 All primers were synthesized by Life Technologies (Breda, The Netherlands). All chemicals needed for PCR were purchased from Promega (Madison, WI).
Statistical Analysis. The statistical program SPSS 8.0 for Windows was used. Information on GSTP1 genotype, smoking, or alcohol was missing in 0, 0, and 11 of the cases and 0, 3, and 1 of controls, respectively. For the purpose of the analysis, the PY of cigarette smoking were categorized as 0, 1-20, 21-40, 41-60, and 60+ PY or in increments of 10 PY. Alcohol consumption was categorized as 0-9, 10-50, and 51+ g/ day. Because there were only three subjects who indicated never to have consumed alcohol, the first category consists of 0-9 g/day. Analyses were conducted for the total group of patients with HNSCC, as well as for oral cavity/oropharyngeal and laryngeal carcinoma separately. Because of small numbers of hypopharyngeal carcinoma, this group was not evaluated separately.
The association between GSTP1 polymorphisms, smoking, alcohol, and HNSCC was modeled through multivariate logistic regression analysis, controlling for age and gender. First, analyses were conducted to examine the associations between GSTP1 genotype and HNSCC, controlling for age, gender, smoking, and alcohol. Specifically, we evaluated whether subjects with GSTP1 AA are less susceptible to HNSCC than those with GSTP1 AB/BB. Likewise associations between smoking and HNSCC or alcohol consumption and HNSCC were examined, controlling for age, gender, and alcohol or smoking, respectively. The strength of the associations was estimated as odds ratios combined with 95% confidence intervals. Subsequently, logistic regression analyses were performed in which the association between smoking or alcohol and HNSCC (and its subgroups) was evaluated within subgroups of the GSTP1 genotype, the wild-type GSTP1 AA group, and the combined heterozygote/homozygote GSTP1 AB/BB group. Likelihood ratio tests were conducted to test statistical significance of regression model terms, as well as to test for trends and interactions. Two-sided p values are reported throughout. Finally, the interaction between smoking and alcohol was evaluated, specifically within subgroups of the GSTP1 genotype. Table 1 shows the frequency analyses for the A to G substitution at codon 313 in the GSTP1 gene, which was examined in 235 HNSCC patients and 285 controls. The GSTP1 BB frequency is low in the control group, as well as in the total HNSCC group or its subgroups. To maintain values for appropriate statistical analysis, we combined the frequencies for GSTP1 AB and GSTP1 BB (Tables  3-5 ).In Table 2 , the frequency distribution is given on the smoking habits and the alcohol con- sumption in HNSCC cases, subgroups of HNSCC, and the control group. The HNSCC group in total, as well as the two subgroups, show a significantly higher tobacco exposure compared with the control group. The control group shows significantly lower alcohol consumption than the HNSCC cases (total or subgroups). In the oral/oropharyngeal subgroup, the rate of daily alcohol consumption more than 51 g/day is much higher compared with the laryngeal subgroup (54.1% vs 30.4%, respectively). Alcohol consumption more than 51 g/day hardly exists in the control group. Table 3 shows that the odds ratios (OR) for alcohol or smoking are similar in the HNSCC group as a total and the two subgroups, except for alcohol consumption more than 51 g/day, when there is a higher OR in the oral/oropharyngeal group. To provide appropriate statistical values, smoking is displayed with an increment of 10 PY. When no adjustment is made for smoking and alcohol (but only for age and gender), the OR for GSTP1 AA vs GSTP1 AB/BB will be 1.31 in the total HNSCC group.
RESULTS
The association between alcohol and smoking and the GSTP1 polymorphisms is shown in Table  4 . For oral/oropharyngeal cases with the GSTP1 AA genotype, alcohol consumption more than doubles the OR compared with the GSTP1 AB/ BB genotype. This is also shown for laryngeal carcinoma. In the oral/oropharyngeal cases, as well as the laryngeal cases with the GSTP1 AB/BB genotype, odds ratios are increased by smoking compared with the GSTP1 AA genotype. We tested for interaction of alcohol consumption between subgroups of GSTP1 in the total HNSCC group; LR-X ‫ס‬ 0.96, df ‫ס‬ 2, p > .05. Also the interaction of smoking between subgroups of GSTP1 in the total HNSCC group is calculated; LR-X ‫ס‬ 6.04, df ‫ס‬ 1, p < .025. In Table 5 we show a significant interaction between smoking and alcohol consumption in HNSCC susceptibility when not adjusted for GSTP1 genotype. The effect of smoking is stronger when more alcohol is consumed (OR increases from 1.27 to 3.53). However, because of small numbers (especially in high alcohol consumption category), interaction between alcohol and smoking and GSTP1 genotype cannot be fully calculated.
DISCUSSION
Glutathione S-transferases are involved in the detoxification of a wide variety of chemical carcinogens, including those derived from cigarette smoke. 5 The enzyme GSTP1-1 is known to catalyze the detoxification of PAH in vitro and may be a major enzyme involved in the detoxification of tobaccorelated metabolic products in vivo. 5 The expression in tissues may vary, depending on site or localization, and immunohistochemical studies have shown a constant and widespread GSTP1-1 expression throughout pharyngeal and laryngeal squamous cell epithelium in both normal and tumor tissue. 10 Earlier we showed that GSTP1-1 is the most important GST enzyme in human head and neck tissues. 30 Therefore, we studied the occurrence of polymorphisms of this gene in patients with different head and neck tumors and controls.
We previously reported that the GSTM1 and GSTT1 null genotypes are not associated with an increased susceptibility for HNSCC. 29 In one of the largest studies performed so far, we found no significant association between risk of HNSCC and occurrence of genetic polymorphisms in the GSTP1 gene. This was also found for oral/ oropharyngeal cancers and laryngeal cancers separately.
The GSTP1-1 enzyme is overexpressed in many neoplastic lesions, such as malignancies of stomach, colorectum, bladder, oral tissue, pharynx, larynx, lung, skin, and breast compared with corresponding normal tissues. 5, [17] [18] [19] [20] [21] [22] 30 However, when estimating GSTP1-1 serum levels in patients with head and neck cancer, we found significantly higher levels compared with controls, but no association with GSTP1 genotype was observed. 31 This may strongly indicate that the overexpression of GSTP1-1 in head and neck cancer is not dependent on genotype but most probably transcriptionally regulated.
We found a strong association between smoking and alcohol consumption and HNSCC susceptibility. Assessment of smoking or alcohol consumption is difficult, especially with respect to patient history for the total accumulative exposure. Exposure usually takes place over many years and is not always consistent. In addition, different cigarette brands may yield completely different nicotine and tar exposures. High consumption of alcohol often is not revealed by patients because of its social unacceptance. It there- fore would help to determine biomarkers such as serum gamma-glutamyltransferase, which could be indicative of recent consumption of alcohol. Development of biomarkers that could indicate the exposure and the period of consumption would be more helpful.
In our control population, GSTP1 BB occurs in 13.6% and GSTP1 AB in 42.5%. Our data for the healthy controls are in agreement with the genotype frequencies in the control populations reported by other researchers.9-14 Similar observations were found for the HNSCC group (12.3% and 38.3%, respectively).
Our data for HNSCC patients are also in agreement with several other studies performed. Lin et al 14 found that polymorphisms in GSTP1 were not associated with increased risk for esophageal cancer. They even found a slightly lower occurrence of GSTP1 AB or BB genotypes in cancer and hyperplasia cases than in controls.
14 Jourenkova-Mironova et al 32 and Matthias et al 10 found no association between the GSTP1 AB or BB genotypes and risk of larynx cancer. Harries et al 9 reported an association between the occurrence of the GSTP1 polymorphism and susceptibility to bladder or testicular cancer but found no association with breast or colon cancer. In other studies, no association was found between the GSTP1 polymorphism and colorectal, lung, or breast cancer. 33, 34 Several other studies, however, revealed a significant correlation between occurrence of GSTP1 polymorphisms and preneoplastic and neoplastic lesions. Lung cancer patients had a significant higher frequency of GSTP1 BB genotype (15.9%) and a lower frequency of GSTP1 AA genotype (38.4%) than controls (9.1% and 51.5%, respectively). 12 Homozygous GSTP1 BB was found significantly more often in patients with Barrett's esophagus and esophageal adenocarcinoma. 35 Matthias et al 10 reported that GSTP1 polymorphism influences susceptibility to pharyngeal but not to laryngeal squamous cell carcinoma. However, when comparing our patient groups in a similar way as Matthias et al 10 (oral cavity/ oropharyngeal SCC and hypopharyngeal SCC versus laryngeal SCC), we did not find a significant difference in the genotype distributions. Ryberg et al 12 reported that patients with the GSTP1 BB genotype had higher DNA adduct levels in lung tissue than the GSTP1 AA genotypes. They also found a linear trend between DNA adduct levels and occurrence rates of GSTP1 B alleles.
The variant genotypes GSTP1 AB and GSTP1 BB showed a different specific activity and affinity for several electrophilic substrates but were identical in their affinity for glutathione. 7, 15 The properties of the variant genotypes were conducted in "in vitro experiments" with recombinant proteins by Ali Osman et al, 7 which, however, does not necessarily provide adequate information on the enzymes and their reactions "in vivo." In agreement with the in vitro results, Watson et al 13 and van Lieshout et al 35 reported a significantly lower conjugating activity with 1-chloro-2,4-dinitrobenzene (CDNB) in lung and esophageal tissue samples, respectively, in patients with GSTP1 AB and GSTP1 BB compared with GSTP1 AA genotypes.
In summary, we found no evidence for a possible genetic predisposition to HNSCC because of genetic polymorphisms in the GSTP1 gene. This suggests that the carcinogens involved in the etiology of HNSCC may not be critically dependent on detoxification by GSTP1-1. Further studies on other combinations of polymorphic genotypes in detoxification enzymes and their relation to local and systemic enzyme concentration seem to be justified.
